The aim of this study is to establish a highly reproducible standard assessment for each companion or complementary PD-L1 antibody in thymic carcinoma and to elucidate the association between the expression of PD-L1 and the clinicopathological features. The gene discussed is CD274; the disease is thymic carcinoma.